WE WILL BEGIN SHORTLY

 To submit text questions to today's presenters, please type your questions into the 'Q&A' box

 Today's presentation is being recorded and will be posted on the Healey & AMG Center for ALS website

https://www.massgeneral.org/neurology/als/news/webinars

HEALEY ALS Platform Trial

Weekly Q&A - Jan 7, 2021

















Healey Center

Sean M. Healey & AMG Center for ALS at Mass General









FAMILY FOUNDATION
























AGENDA

- Updates on the HEALEY ALS Platform Trial
 - Study Treatments
 - Sites
 - Enrollment
- How to stay in touch and find a site near you

YOUR QUESTIONS


Perpetual Adaptive Trial Randomization Ratio 3:1; Shared Placebo Open Label Extension offered



Screening

24 weeks on study drug (active:placebo = 3:1)

How to Find a Center Near You



34 sites are actively enrolling

Contact Info of Participating Sites by State



https://www.massgeneral.org/neurology/als/research/platform-trial-sites

List of enrolling sites as of Jan 7, 2021 34 sites are enrolling

- **☑** Texas Neurology
- **™** MGH
- **W** UTHSCSA
- **™** Holy Cross Hospital
- **™** Thomas Jefferson
- **Mathodist** Houston Methodist
- Menry Ford Health System
- **Mathematical Services** Barrow Neurological Institute
- **™** Ohio State University
- **™** Northwestern University
- **™** University of Chicago
- **Wake Forest**
- **☑** University of Nebraska Medical Center
- ✓ Loma Linda
- **☑ University of Washington**
- ✓ University of Iowa

- **Washington University**
- **☑** University of Michigan
- **☞ Forbes Norris MDA/ALS Research Center, CPMC**
- **™** Penn State Hershey
- ✓ UMass
- **☑** University of Miami
- **☑** University of Colorado
- **™** University of Florida
- **™** University of South Florida
- **☑** Columbia University
- **✓ University of Virginia**
- **Emory**
- **☑** University of Maryland
- **SUNY Upstate**
- ☑ Beth Israel Deaconess Medical Center

Enrollment Updates (as of Jan 7, 2021)

- 257 individuals with ALS signed informed consent
- 203 individuals were assigned to a regimen
- 181 are currently receiving study drug (active or placebo)

We will continue to update the ALS community on enrollment (website, webinars)

Expanded Access Program (EAP)

- Great interest in EAPs from the patient community
- Long term goal is to build an EAP in parallel to the Platform Trial
 - The idea came from the Patient Advisory Committee
 - The EAP would allow access to patients who are not eligible for the trial
- We are working to achieve this goal
 - We are actively fundraising to support this effort
 - One grant has been received from I AM ALS to start building the EAP

https://www.massgeneral.org/neurology/als/news/2020-12-18-iamals-eap-grant

Patient Navigator

Catherine Small Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

For More Updates

Weekly webinars

The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have

Find the schedule and registration links on our website

https://www.massgeneral.org/neurology/als/research/platform-trial-news/

Coming up: Drug mechanism of action and science webinars

Jan 21- Prilenia/Pridopidine

Feb 4 - Clene/CNM-Au8

Feb 18- Biohaven/Verdiperstat

Feb 25- Ra Pharma/Zilucoplan